Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The MDM2-p53 interaction Moll UM; Petrenko OMol Cancer Res 2003[Dec]; 1 (14): 1001-8Activation of the p53 protein protects the organism against the propagation of cells that carry damaged DNA with potentially oncogenic mutations. MDM2, a p53-specific E3 ubiquitin ligase, is the principal cellular antagonist of p53, acting to limit the p53 growth-suppressive function in unstressed cells. In unstressed cells, MDM2 constantly monoubiquitinates p53 and thus is the critical step in mediating its degradation by nuclear and cytoplasmic proteasomes. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Disruption of the p53-MDM2 complex by multiple routes is the pivotal event for p53 activation, leading to p53 induction and its biological response. Because the p53-MDM2 interaction is structurally and biologically well understood, the design of small lipophilic molecules that disrupt or prevent it has become an important target for cancer therapy.|Animals[MESH]|Binding Sites[MESH]|Cysteine Endopeptidases/metabolism[MESH]|Humans[MESH]|Multienzyme Complexes/metabolism[MESH]|Nuclear Proteins/*metabolism[MESH]|Proteasome Endopeptidase Complex[MESH]|Protein Binding[MESH]|Proto-Oncogene Proteins c-mdm2[MESH]|Proto-Oncogene Proteins/*metabolism[MESH]|Tumor Suppressor Protein p14ARF/metabolism[MESH]|Tumor Suppressor Protein p53/*metabolism[MESH]|Ubiquitin/metabolism[MESH] |
